Inimmune
PrivateLast Round
Grant
Feb 1, 2024
Total Funding Raised
$46.58M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Inimmune is a biotechnology company that discovers and develops novel immunotherapeutics and vaccine adjuvants for the treatment of allergy, autoimmunity, infectious diseases, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inimmune Comparables
Compare Inimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adjuvance Technologies | 87% | |
| Access to Advanced Health Institute | 81% | |
| ImmunAdd Inc. | 78% |
For institutional investors. Book with your work email.
Inimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 1, 2024 | ||||
| Series A | Jul 9, 2020 | ||||
| Grant | Jul 1, 2020 | ||||
| Grant | Jun 25, 2018 | ||||
| Grant | Feb 14, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Inimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Two Bear Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Presented data at the Society for Immunotherapy of Cancer Annual Meeting.
- Nov 6, 2026
Phase 1 data for INI-4001 showed immune activation in advanced solid tumors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
Inimmune presents Phase 1 INI-4001 data in a late-breaking poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on Nov 6th '26.
- attends_eventOct 22, 2026
Inimmune's Chief Executive Officer, Dr. David Burkhart, is scheduled to chair the Vaccine Delivery Workshop at the World Vaccine Congress Europe in the Netherlands on Oct 19th-21st '26.
- attends_eventOct 22, 2026
Inimmune attends World Vaccine Congress Europe in the Netherlands on Oct 19th-21st '26, where CEO Dr. David Burkhart is to chair the Vaccine Delivery Workshop.
For institutional investors. Book with your work email.
Inimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Inimmune's valuation, stock price, and market status.
Is Inimmune a public or private company?
Inimmune is a private company.
What is the current stock price of Inimmune?
Inimmune is a private company, so its shares have no public market price. Caplight tracks Inimmune's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inimmune worth (valuation)?
Valuation information for Inimmune is not publicly available.
Can I buy Inimmune stock?
Inimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inimmune's last funding round?
Inimmune's most recent funding round was Grant on February 1, 2024.
Who are the main investors in Inimmune?
Key investors in Inimmune include Two Bear Capital.
Will Inimmune IPO soon?
No public IPO plans have been announced for Inimmune.
How can I track Inimmune secondary market activity?
Caplight tracks bids, offers, and trades in Inimmune's shares on secondary markets.